News
Targetable genetic alterations found in 41% of soft tissue sarcomas
Next-generation sequencing results might prove useful for guiding targeted therapy that could improve the treatment outcomes of patients with...
News
FDA approves test to screen donated blood for Zika virus
The cobas Zika test is the first test approved for screening the blood supply.
News
Vemurafenib granted sNDA, priority review for Erdheim-Chester disease
Vemurafenib (Zelboraf) has been granted a supplemental new drug application and priority review by the Food and Drug Administration for the...
News
Liposomal daunorubicin and cytarabine approved for t-AML, AML-MRC
Vyxeos, a liposome-encapsulated combination of daunorubicin and cytarabine, has been approved for the treatment of adults with newly-diagnosed...
News
Ibrutinib becomes first FDA-approved treatment for chronic GVHD
Ibrutinib (Imbruvica) added another notch on its indications belt with its August 2 approval by the U.S. Food and Drug Administration for the...
News
Enasidenib gets FDA approval for AML with IDH2 mutations
“Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation,” said Richard...
News
Less lenalidomide may be more in frail elderly multiple myeloma patients
Starting patients on a reduced dose and increasing it gradually while monitoring carefully for adverse events, meant patients did not have to stop...
News
FLT3-L level may point to relapsed/refractory multiple myeloma
FLT3-ligand (FLT3-L) levels exceeding 92 pg/mL in bone marrow and 121 pg/mL in peripheral blood are associated with relapsed and refractory...
News
Antibody from AML survivor may prove therapeutic
CHICAGO – A treatment for acute myeloid leukemia may be derived from the immortalized B cells of an AML patient who was cured after allogeneic...
News
Lenalidomide consolidation linked to extended overall survival in non-del(11q) CLL
CHICAGO – Lenalidomide consolidation therapy was associated with an extended survival plateau for patients with non-del(11q) chronic lymphocytic...
News
Bendamustine plus rituximab may have edge for treating indolent NHL, MCL
CHICAGO – Bendamustine plus rituximab may have some advantages for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle cell...
News
Severe health conditions decline in childhood cancer survivors
CHICAGO – Certain types of severe morbidity have steadily declined in childhood cancer survivors.
Video
VIDEO: Childhood cancer survivors living longer with fewer severe health problems
Steady improvements seen in participants in the Childhood Cancer Survivor Study.
News
Early allo SCT advised for high-risk mantle cell lymphoma
High-risk patients with mantle cell lymphoma who have a matched related donor have a better chance for survival if they do not delay allogeneic...
News
ALC/AMC prognostic in mantle cell lymphoma
The peripheral blood absolute lymphocyte-to-monocyte ratio (ALC/AMC) was prognostic for overall survival in mantle cell lymphoma patients who have...